Dr. Paul D. Rosenblit, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 433
Licensed in California since 1982, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
CA license A39224 (first issued 1982; current) -
Specialist
CA license A039224
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
- Providence St. Joseph Hospital Orange, CA
- Memorialcare Orange Coast Medical Center Fountain Valley, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 433
- Services billed
- 890
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 870 | 454 |
| New patient office or other outpatient visit, 60-74 minutes | 55 | 55 |
| Established patient office or other outpatient visit, 40-54 minutes | 20 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ezetimibe Other prescribers in Huntington Beach, CA | 1,309 |
| Pioglitazone Hcl Other prescribers in Huntington Beach, CA | 1,182 |
| Levothyroxine Sodium Other prescribers in Huntington Beach, CA | 1,070 |
| Rosuvastatin Calcium Other prescribers in Huntington Beach, CA | 928 |
| Atorvastatin Calcium Other prescribers in Huntington Beach, CA | 902 |
| Metformin Hcl Other prescribers in Huntington Beach, CA | 765 |
| Jardiance (empagliflozin) Other prescribers in Huntington Beach, CA | 661 |
| Ozempic (semaglutide) Other prescribers in Huntington Beach, CA | 436 |
| Trulicity (dulaglutide) Other prescribers in Huntington Beach, CA | 371 |
| Metoprolol Succinate Other prescribers in Huntington Beach, CA | 309 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 59 payments worth $8,986 in total to this clinician.
| Ionis Pharmaceuticals, Inc. | $6,926 |
|---|---|
| Novo Nordisk Inc | $286 |
| Amgen Inc. | $278 |
| Bayer HealthCare Pharmaceuticals Inc. | $259 |
| Ascendis Pharma Endocrinology Inc | $201 |
| Corcept Therapeutics | $159 |
| Recordati_rare_diseases_inc. | $132 |
| Kyowa Kirin, Inc. | $122 |
| Consulting Fee | $6,751 |
|---|---|
| Food and Beverage | $2,130 |
| Travel and Lodging | $63.00 |
| Education | $42.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ionis Pharmaceuticals, Inc. Dec 13, 2025 | Consulting Fee OLEZARSEN · CARDIOLOGY | $6,751 |
| Ionis Pharmaceuticals, Inc. Dec 13, 2025 | Travel and Lodging OLEZARSEN · CARDIOLOGY · travel to CARLSBAD, CA · in-kind | $63.00 |
| Mannkind Corporation Mar 29, 2025 | Education AFREZZA · DIABETES MEDICINE · in-kind | $42.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $44,826 in research payments for these studies, mostly to the institutions running them.
- Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - Study name not reported
Novo Nordisk As - Study name not reported
Ionis Pharmaceuticals, Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.